James Wallace Esq.

Wiley Rein LLP
Wallace, Jr., James H.(1)

Jim Wallace, a founding Partner of , has more than 30 years of experience litigating patents in the fields of communications satellites, data transmission, network interface devices, Internet business methods, pharmaceuticals, biotechnology, and semiconductors.

He secured, on behalf of client NTP Inc., a $612.5 million patent infringement settlement with Research In Motion Ltd. (RIM), the maker of BlackBerry wireless email devices. The settlement, one of the largest ever of its kind, resolved a fiercely contested, high-profile patent case stemming from a 2002 jury trial in which the firm successfully argued that RIM's core BlackBerry line of wireless email products, software and services willfully infringed NTP patents.

Mr. Wallace litigated numerous pharmaceutical patent cases, including cetuximab (Erbitux®), loratadine (Claritin®), oxybutynin chloride (Ditropan XL®), carbidopa/levodopa (Sinemet® CR), tamoxifen citrate (Nolvadex®), allopurinol (Zyloprim®), tPA (Activase®), omeprazole (Prilosec®), cyclobenzaprine HCl (Amrix®), erlotinib (Tarceva®), interferon (Roferon®-A), levofloxacin (Levaquin®), dutasteride (Avodart®), fenofibrate (Antara®), and tolterodine tartrate (Detrol® LA).

Mr. Wallace received his B.S.E.E. from University of South Carolina, and his J.D. from Georgetown University.